Viral Vector-Based Gene Therapy Development and Support

Solutions to help you streamline viral vector-based gene therapy asset development from the lab to the clinic.

Consistent quality, trial execution, and production expertise

Gene therapy has emerged as a promising approach to genetic and acquired disease treatment. At the heart of this revolutionary technology is the use of viral vectors, which serve as delivery vehicles for introducing therapeutic genes to target cells. Lean on our team to help you simplify and reduce risk during viral vector-based gene therapy development from discovery through commercialization.

75 gene therapy trials were supported by our clinical research services*

165+ cGMP batches of viral vector-gene therapy products were produced*

4 new gene therapy workflow-enabling products launched*

Insights and resources to support your work

Let the following resources help guide your viral vector-based gene therapy development process. 

Gene therapy: from set-up to scale-up

Whether you’re developing in-house capabilities or outsourcing your projects, let us connect you with scalable solutions to meet your unique specifications.

Considerations for your gene therapy manufacturing strategy

See an overview of viral vector production and purification solutions and the factors that may influence the decision to develop in-house or to seek specialist help.

A Developing, Growing and Changing Regulatory Landscape

Heather Myler, Ph.D., director, PPD Laboratories, bioanalytical lab, discusses regulatory changes in the field.

Benefits of an integrated approach to gene therapy development and manufacturing

Discover the development and commercialization of viral vectors for gene therapy, so you can navigate these hurdles and deliver the project in a timely, cost-effective manner.

Viral vector-based gene therapy development workflow and our solutions

Our team is here to help you streamline gene therapy asset development from the lab to the clinic. Learn more about each workflow step and our selected solutions by opening the sections below.

Once the target is selected and validated, your first key step is to produce and screen for a viral vector that can optimally deliver your gene therapy. Identifying the right vector is an essential part of this workflow.

*All statistics are based on data from 2018 to 2023.

Intended use of the products mentioned on this page vary. For specific intended use statements please refer to the product label.